iRhythm Holdings, Inc

iRhythm Holdings, Inc(IRTC)の株式分析

$120.250

+4.052 (+3.37%)終値時点

Loading chart…
High
121.200
Open
117.230
VWAP
118.83
Vol
439.40K
Mkt Cap
3.25B
Low
115.040
Amount
52.21M
EV/EBITDA, TTM
41.38

iRhythm Holdings, Inc. is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. The Company's principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. The Company provides Zio ambulatory cardiac monitoring services, including long-term continuous monitoring (LTCM), short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using a proprietary system that combines an FDA-cleared and CE-marked wire-free, patch-based, 14-day wearable biosensor that continuously records ECG data, with a proprietary FDA-cleared, CE-marked, Japan PDMA approved cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

AI analysis of iRhythm Holdings, Inc (IRTC)

buy

iRhythm Technologies Inc is a good buy right now due to its recent strong Q2 results, which showed sales of $224.17 million and a narrowed net loss of only $0.381 million. Additionally, the company raised its full-year revenue guidance to $880 million–$890 million, reflecting an expected growth of 18%-19% year-over-year. However, the stock has a high forward P/E ratio of 500, indicating that it may be overvalued if growth does not meet expectations.

Analyst Ratings (4)

+84.62% upside
Buy
3 Buy
1 Hold
0 Sell
Current: 120.25
安値
205.00
平均
222.00
高値
244.00

Truist

2026-08-10

目標株価

$168

Buy

Canaccord

2026-08-07

目標株価

$196

Buy

Baird

2026-08-07

目標株価

$165

Outperform

Stephens

2026-07-22

目標株価

$160

Overweight

Truist

2026-07-16

目標株価

$160

Buy

バリュエーション指標

The current forward P/E ratio for iRhythm Holdings, Inc (IRTC) is 500.00, compared to its 5-year average forward P/E of -14.76.

Forward P/E

Strongly Overvalued
5Y Average P/E
-14.76
Current P/E
500.00
割高
212.03
割安
-241.54

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
184.47
Current EV/EBITDA
41.38
割高
1088.42
割安
-719.48

Forward P/S

Undervalued
5Y Average P/S
6.13
Current P/S
3.67
割高
8.00
割安
4.26

Alphio AI Price Scenarios for IRTC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%IRTC

$186.19

シナリオ価格

B

Base

Base · 50%IRTC

$184.84

シナリオ価格

B

Bear

Bear · 25%IRTC

$178.24

シナリオ価格

Whales holding IRTC

R

Rock Springs Capital Management LP

+ HoldingIRTC

+18.51%

3M Return

P

Perceptive Advisors LLC

+ HoldingIRTC

+4.39%

3M Return

N

Next Century Growth Investors LLC

+ HoldingIRTC

-10.44%

3M Return

IRTC FAQ — answered by Alphio AI

iRhythm Holdings, Inc. is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. The Company's principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. The Company provides Zio ambulatory cardiac monitoring services, including long-term continuous monitoring (LTCM), short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using a proprietary system that combines an FDA-cleared and CE-marked wire-free, patch-based, 14-day wearable biosensor that continuously records ECG data, with a proprietary FDA-cleared, CE-marked, Japan PDMA approved cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

iRhythm Technologies Inc is a good buy right now due to its recent strong Q2 results, which showed sales of $224.17 million and a narrowed net loss of only $0.381 million. Additionally, the company raised its full-year revenue guidance to $880 million–$890 million, reflecting an expected growth of 18%-19% year-over-year. However, the stock has a high forward P/E ratio of 500, indicating that it may be overvalued if growth does not meet expectations.

4 analysts cover IRTC: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 222.00.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める